banner

LEXOLOGY

  • email
  • twitter
  • linkedin
  • facebook
FDA Regulatory and Compliance Monthly Recap — February 2019
FDA publishes draft guidance describing pathways for combination product review The guidance outlines the principles for premarket review of...

FDA's loud and clear message: Engage with FDA early and formally Blog MoFo Life Sciences
On February 10, 2022, the U.S. Food and Drug Administration (FDA) held a public Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the...

The Impact of Brexit on Medicinal Product Marketing Authorisations
Following our article “Brexit with or without a deal: Consequences for pharmaceutical companies”, which provided a general overview of the...

MHRA Provides Further Guidance on No-Deal Brexit Plans Blog Life Sciences Hub
The MHRA has issued updated guidance on its plans for the regulation of medicines, medical devices and clinical trials in the event that the...

China Proposes New Draft Laws on Drug and Vaccine Management
The Chinese government has issued draft amendments to the Drug Administration Law and a draft Vaccine Administration Law for public comment....

Life Sciences: Product Regulation and Liability in Sweden
Use the Lexology Navigator tool to compare the answers in this article with those from other jurisdictions. Trends and developments Legal...

Ninth Circuit Finds No Private Cause of Action Against Pharmaceutical Compounder Blog Drug and Device Law
It has been just about two years since the Central District of California dismissed the claims in Nexus Pharmaceuticals, Inc. v. Central...